-
Published 10/6/2025
Cournoyer L, Liu Y, Jaroch DB, Hullinger TG, Cox BF, Katz SC, LaPorte J, Layman IB, Ballarin A, Ghosh CC, Guha P. Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models. Front Oncol. 2025; 15:1655794. PMID: 41122641.
-
Published 7/22/2024
Ghosh CC, Cournoyer L, Liu Y, Ballarin A, Layman IB, LaPorte J, Morrissey M, Fraser K, Perati S, Cox BF, Yakirevich E, Treaba DO, Murtha TD, Guha P, Katz SC, Davar D. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. J Immunother Cancer. 2024 Jul 22; 12(7). PMID: 39038918.
-
Published 6/15/2022
Sullivan KM, Jiang X, Guha P, Lausted C, Carter JA, Hsu C, Labadie KP, Kohli K, Kenerson HL, Daniel SK, Yan X, Meng C, Abbasi A, Chan M, Seo YD, Park JO, Crispe IN, Yeung RS, Kim TS, Gujral TS, Tian Q, Katz SC, Pillarisetty VG. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut. 2023 Feb; 72(2):325-337. PMID: 35705369.
-
Published 6/14/2022
Ghosh CC, Heatherton KR, Connell KPO, Alexander IS, Greer DA, LaPorte J, Guha P, Cox BF, Katz SC. Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition. Cancer Gene Ther. 2022 Dec; 29(12):1854-1865. PMID: 35697801.
-
Published 3/11/2022
Guha P, Heatherton KR, O'Connell KP, Alexander IS, Katz SC. Assessing the Future of Solid Tumor Immunotherapy. Biomedicines. 2022 Mar 11; 10(3). PMID: 35327456.